BRNHF (Broncus Holding) Research & Development: $7.77 Mil (TTM As of Dec. 2025)


BRNHF Broncus Holding Corp BRNHF
39 GF Score
Price $0.08
! 7 Warning Signs
View Full Analysis

What is Broncus Holding Research & Development?

Broncus Holding BRNHF 39 Research & Development is $7.77 Mil as of Dec. 2025. GuruFocus rates BRNHF with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Broncus Holding's Research & Development for the six months ended in Dec. 2025 was $3.32 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $7.77 Mil.

Broncus Holding  (OTCPK:BRNHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Broncus Holding Research & Development Related Terms

Broncus Holding Research & Development Historical Data

* Premium members only.

The historical data trend for Broncus Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Broncus Holding Research & Development Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 16.76 19.17 20.15 11.47 7.77

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.92 6.49 4.98 4.46 3.32
BRNHF
39GF Score
Broncus Holding Corp BRNHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Broncus Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $7.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $7.77 Mil mean?
Broncus Holding (BRNHF) has a Research & Development of $7.77 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Broncus Holding and its competitors.
Is Broncus Holding's Research & Development too high?
Broncus Holding's current Research & Development is $7.77 Mil. Overall, Broncus Holding has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's Research & Development compare to ABT and SYK?
Broncus Holding's Research & Development of $7.77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Broncus Holding and its competitors. Broncus Holding's current Research & Development is $7.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Broncus Holding (BRNHF) has a current Research & Development of $7.77 Mil. The current Research & Development is $7.77 Mil. Broncus Holding's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Broncus Holding (BRNHF), the current Research & Development is $7.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Broncus Holding Business Description

Other Exchanges 02216:Hong Kong
Address No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
39GF Score

Get the complete analysis for BRNHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price